5-methyltetrahydrofolate Survival and Inflammation in ESRD Patients
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
A randomized prospective study was done to determine whether i.v. 5-methyltetrahydrofolate vs
oral folate improved survival in ESRD patients. Homocysteine, CRP, Lp(a), albumin, folates,
vitamin B6 and B12 were checked. The 5-MTHF treated group was associated with lowered C
reactive protein and higher survival than the folate treated group.
Phase:
N/A
Details
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna St. Orsola Hospital